<DOC>
	<DOCNO>NCT01291199</DOCNO>
	<brief_summary>The purpose study determine whether vardenafil effective improve clinical symptom peripheral blood flow patient primary secondary Raynaud phenomenon .</brief_summary>
	<brief_title>Effects Vardenafil Clinical Symptoms Peripheral Blood Flow Patients With Raynaud 's Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Raynaud Disease</mesh_term>
	<mesh_term>Phosphodiesterase 5 Inhibitors</mesh_term>
	<mesh_term>Vardenafil Dihydrochloride</mesh_term>
	<criteria>raynaudsyndrome ( primary secondary ) &gt; 1 year duration age ≥ 18 year ; ≤ 80 year informed consent negative pregnancy test woman childbearing age unstable organic , psychiatric addictive disease , opinion investigator might result unsuccessful / unreliable participation premature termination trial know contraindication PDE 5inhibitors ( intolerance , therapy nitrate inhibitor CYP3A4 , etc . ) extensive necrosis finger tip pigmentary retinopathy verification HbsAg hepatitis C carrier unstable angina heart failure ( NYHA III IV ) valve defect high degree ( particularly aortic stenosis hypertrophic obstructive cardiomyopathy ) myocardial infarction , stroke lifethreatening cardiac arrhythmia within last 6 month uncontrolled atrial fibrillation / flutter heart rate &gt; 100 bpm prolong QTcinterval ( &gt; 450 msec ) congenital longQTsyndrome hypokalemia severe acute chronic liver disease , might lead priapism ( sickle cell anemia , leucemia ) hemophilia active peptic ulcer arterial hypotension ( systolic blood pressure rest &lt; 90 mmHg ) arterial hypertension ( systolic blood pressure rest &gt; 170 mmHg diastolic blood pressure rest &gt; 110 mmHg ) malignancy within last 5 year ( except squamous basal cell skin cancer ) patient injuries spinal cord central nervous system patient severe chronic kidney disease ( creatinin clearance &lt; 30 ml ) patient mild severe liver disease ( ChildPugh AC ) Age 18 80 prohibit concomitant medication study : nitrate NOdonators ( include amylnitrit ) anticoagulative drug except inhibitor thrombocyte function androgen ( testosterone ) antiandrogens strong inhibitor cytochrome P4503A4 : potent HIVProteaseinhibitors ( ritonavir , indinavir ) antimycotic like itraconazole ketoconazole ( topical application allow ) erythromycin grapefruitjuice product contain grapefruitjuice study medication ( include placebo ) 30 day study inclusion therapy erectile dysfunction ( include sildenafil , sublingual apomorphin , MUSE® , intracavernous injection vacuum pump ) therapy erectile dysfunction within 4 week trial period nebivolol alphablockers Calcium antagonists medication prolong QTinterval abnormal lab test like : serumcreatinine &gt; 3 mg/dl visit 1 GOT GPT &gt; 3 x reference limit set diabetes mellitus HbA1c &gt; 9 % patient willing disclaim therapy erectile dysfunction vacuum pump , intravenous injection , sildenafil therapy trial severe migraine ( moth last 6 month ) intolerance study medication patient able understand information inform consent due mental disorder linguistic barrier person live institution directly federal government control due court order patient refuse renounce drinking grapefruit juice trial woman pregnant lactate woman protect pregnancy ( intake oral contraceptive alone insufficient ; highly effective method birth control use failure rate &lt; 1 % ; barrier : implant , intrauterinedevices ( IUD´s ) , diaphragm , condom , abstinence , partner vasectomize , spermicide ) patient participate interventional study within 30 day study inclusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>double-blind placebo control cross-over study</keyword>
</DOC>